Results 31 to 40 of about 4,412 (151)

Side Effects and Efficacy of COVID-19 Vaccines among the Egyptian Population

Vaccines, 2022
Background: Knowledge about a vaccine’s side effects and efficacy is important to improving public vaccine acceptance. This study aimed to detect the safety and efficacy of vaccines among the Egyptian population.
Marwa O. Elgendy, Ahmed O. El-Gendy, Sarah Mahmoud, Tarek Yehia Mohammed, Mohamed E. A. Abdelrahim, Ahmed M. Sayed   +5 more
doaj   +1 more source

Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease

Vaccines, 2022
Vaccination against coronavirus disease 2019 (COVID-19) has become an important public health solution. Developing a safe and effective vaccine against COVID-19 is a viable long-term solution to control the pandemic.
Chao Wang, Lin-Yi Chen, Qing-Bin Lu, Fuqiang Cui   +3 more
doaj   +1 more source

Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine. [PDF]

, 2023
The coronavirus SARS-CoV-2 has mutated quickly and caused significant global damage. This study characterizes two mRNA vaccines ZSVG-02 (Delta) and ZSVG-02-O (Omicron BA.1), and associating heterologous prime-boost strategy following the prime of a most ...
Cai, Rujie, Cheng, Hang, Cheng, Xinhua, Ding, Jun, Fan, Huifen, Hou, Fujun, Hu, Chunxia, Hua, Xianwu, Huang, Hongwei, Jia, Rui, Jia, William, Li, Jing, Li, Xinguo, Li, Yuwei, Lin, Kang, Liu, Fei, Liu, Lianxiao, Liu, Xiaohu, Liu, Xiaoke, Lu, Changrui, Lu, Jia, Pan, Xinping, Wang, Hui, Wang, Xuewei, Wang, Zejun, Xu, Fangjingwei, Xu, Jiang, Yang, Guohuan, Yang, Xiaoming, Yu, Zhibin, Zhang, Qiu, Zhang, Yuntao, Zhao, Ronghua   +32 more
core   +1 more source

A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants. [PDF]

, 2022
Large-scale populations in the world have been vaccinated with COVID-19 vaccines, however, breakthrough infections of SARS-CoV-2 are still growing rapidly due to the emergence of immune-evasive variants, especially Omicron.
Du, Li, Han, Zi, Hou, Jun, Hou, Ya, Huang, Wei, Jin, Yu, Lei, Wenwen, Lei, Ze, Li, Qi, Li, Xin, Li, Xin, Liang, Yu, Liu, Ning, Liu, Zhao, Shao, Shuai, Shen, Fu, Su, Ji, Wang, Hui, Wu, Gui, Wu, Jin, Xu, Ke, Zhang, Jin, Zhang, Jing, Zhang, Xue, Zheng, Xiang   +24 more
core   +1 more source

Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon [PDF]

, 2021
Facing new COVID-19 waves, the effectiveness of BBIBP-CorV has been noted to be low in countries whose populations were already administered two doses of the vaccine.
Abdallah, Dania Issam, Bader, Mohammad, Bizri, Abdul Rahman N., el-Hassan, Salam, Jisr, Tamima El, Jizi, Ihab, Mekdashi, Rana, Moghnieh, Rima A., Sayegh, Mohamed H.   +8 more
core   +1 more source

Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine

Vaccines, 2022
Coronavirus disease 2019 (COVID-19) booster vaccination is being comprehensively evaluated globally due to waning immunity and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants.
Jira Chansaenroj, Nungruthai Suntronwong, Sitthichai Kanokudom, Suvichada Assawakosri, Ritthideach Yorsaeng, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Lakana Wongsrisang, Donchida Srimuan, Thaksaporn Thatsanatorn, Thanunrat Thongmee, Chompoonut Auphimai, Pornjarim Nilyanimit, Nasamon Wanlapakorn, Natthinee Sudhinaraset, Yong Poovorawan   +15 more
doaj   +1 more source

Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina [PDF]

, 2022
The COVID-19 pandemic has particularly affected older adults residing in nursing homes, resulting in high rates of hospitalisation and death. Here, we evaluated the longitudinal humoral response and neutralising capacity in plasma samples of volunteers ...
Ana Ceballos (337981), Andrea P. Silva (13862279), Andrea V. Gamarnik (9986936), Andrés H. Rossi (13862318), Antonella S. Ríos (13862294), Bianca Mazzitelli (13862306), Carla A. Pascuale (9074909), Christian Ballejo (13862288), Diego S. Ojeda (9986906), Esteban A. Miglietta (13862282), Jimena Marro (13862300), Laboratorio SeVa Group (13862321), Lila Ramis (13862297), Lucía López Miranda (13862291), María F. Aguirre (13862312), María M. Gonzalez Lopez Ledesma (13862309), Melina Salvatori (10204125), Pablo Rall (13862285), Pamela E. Rodriguez (13862276), PAMI Group (13862324), Verónica Poncet (13862303), Yanina Miragaya (13862315)   +21 more
core   +1 more source

Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru

Vaccines, 2023
We evaluated neutralizing antibody (NAbs) levels as a protective factor against vaccine breakthrough infection (VBI) in healthcare workers (HCWs) during the third COVID-19 wave in Peru.
Miguel Hueda-Zavaleta, Juan C. Gómez de la Torre, José Alonso Cáceres-DelAguila, Cecilia Muro-Rojo, Nathalia De La Cruz-Escurra, Cesar Copaja-Corzo, Carlos J. Aragón-Ayala, Vicente A. Benítes-Zapata   +7 more
doaj   +1 more source

Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants

Genome Medicine, 2022
Background The emergence of SARS-CoV-2 Omicron subvariants has raised questions regarding resistance to immunity by natural infection or immunization.
Xue-Jun Wang, Lin Yao, Hong-Yun Zhang, Ka-Li Zhu, Jing Zhao, Bing-Dong Zhan, Yi-Ke Li, Xue-Juan He, Cong Huang, Zhuang-Ye Wang, Ming-Dong Jiang, Peng Yang, Yang Yang, Guo-Lin Wang, Sheng-Qi Wang, Er-Hei Dai, Hui-Xia Gao, Mai-Juan Ma   +17 more
doaj   +1 more source

Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination

Frontiers in Immunology, 2022
BackgroundBBIBP-CorV and CoronaVac inactivated COVID-19 vaccines are widely-used, World Health Organization-emergency-listed vaccines. Understanding antibody level changes over time after vaccination is important for booster dose policies.
Fuzhen Wang, Baoying Huang, Huakun Lv, Lizhong Feng, Weihong Ren, Xiaoqi Wang, Lin Tang, Qianqian Liu, Dan Wu, Hui Zheng, Zhijie An, Yao Deng, Li Zhao, Fei Ye, Wenling Wang, Hangjie Zhang, Shaoying Chang, Yuting Liao, Fengyang Chen, Lance E. Rodewald, George F. Gao, Zundong Yin, Wenjie Tan   +22 more
doaj   +1 more source